中国P站

Carotid stenosis, the narrowing of the carotid arteries due to atherosclerotic plaque buildup, stands as a significant contributor to ischemic stroke, one of the leading causes of death and disability worldwide. These arteries, located on either side of the neck, supply oxygenated blood to the brain, and their obstruction can lead to transient ischemic attacks (TIAs) or full-blown strokes when plaques rupture or emboli dislodge. The prevalence of carotid stenosis increases with age and is closely tied to risk factors such as hypertension, diabetes, smoking, and hyperlipidemia, making it a critical target for intervention in an aging global population. While medical management with antiplatelet agents, statins, and lifestyle modifications plays a foundational role, surgical interventions have emerged as pivotal strategies for preventing stroke in patients with significant stenosis, typically defined as 50-99% occlusion. Two primary surgical approaches dominate the landscape: carotid endarterectomy (CEA), the traditional gold standard, and carotid artery stenting (CAS), a less invasive alternative introduced in recent decades [1]. Both procedures aim to restore adequate blood flow and reduce the risk of cerebrovascular events, yet their long-term outcomes remain a subject of intense scrutiny and debate. This manuscript explores the role of these surgical interventions in managing carotid stenosis, delving into their efficacy, complications, and sustained impact on patient health over time [2].

The urgency of optimizing carotid stenosis management is underscored by its public health implications. Stroke accounts for approximately 5.5 million deaths annually, with survivors often facing profound physical and cognitive impairments. For symptomatic patients those who have experienced TIAs or minor strokes surgical intervention is often recommended when stenosis exceeds 70%, as supported by landmark trials like the North American Symptomatic Carotid Endarterectomy Trial (NASCET) [3]. For asymptomatic patients, the decision is less straightforward, balancing the risk of stroke against procedural hazards. Advances in imaging, such as duplex ultrasonography and magnetic resonance angiography, have improved the ability to identify high-risk plaques, refining patient selection for surgery. However, as surgical techniques evolve and patient demographics shift, understanding the long-term outcomes of CEA and CAS becomes essential for guiding clinical practice and improving quality of life. This exploration seeks to synthesize current evidence, offering a comprehensive view of how these interventions shape the trajectory of carotid stenosis over years and decades [4].

Description

Carotid endarterectomy, introduced in the 1950s, involves surgically removing atherosclerotic plaque from the inner lining of the carotid artery through an incision in the neck. The procedure requires general or local anesthesia and meticulous closure of the artery, often with a patch to prevent restenosis. CEA has been extensively validated by randomized controlled trials, demonstrating a significant reduction in stroke risk for symptomatic patients with severe stenosis. The NASCET trial, for instance, found that CEA reduced the five-year stroke risk from 26% to 9% in patients with 70-99% stenosis, a benefit that persists over a decade with proper follow-up care. For asymptomatic patients, the Asymptomatic Carotid Atherosclerosis Study (ACAS) reported a more modest but still significant reduction in stroke risk, from 11% to 5% over five years, provided stenosis exceeds 60% [5]. Long-term outcomes of CEA are generally favorable, with durability of the repair evidenced by low rates of restenosis (typically 5-10% over 10 years) when performed by experienced surgeons. However, the procedure is not without risks: perioperative stroke or death occurs in 2-3% of asymptomatic cases and up to 6% in symptomatic patients, often due to embolization or vessel occlusion during surgery. Myocardial infarction, cranial nerve injury, and wound complications further complicate recovery, particularly in older patients with comorbidities.

Carotid artery stenting, by contrast, represents a newer, endovascular approach, where a stent is deployed via catheter to scaffold the narrowed artery open, often accompanied by an embolic protection device to capture debris. CAS gained traction in the 1990s as an alternative for patients deemed high-risk for CEA, such as those with severe cardiac disease, prior neck surgery, or contralateral carotid occlusion. Trials like the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) have shown CAS to be broadly equivalent to CEA in terms of long-term stroke prevention, with a 10-year ipsilateral stroke rate of approximately 7% for both procedures in symptomatic and asymptomatic patients. However, CAS carries a higher periprocedural stroke risk, particularly in the first 30 days (4-6% versus 2-3% for CEA), attributed to plaque dislodgement during stent placement. Over time, this risk equalizes, and CAS demonstrates durability similar to CEA, with restenosis rates of 6-12% over five to ten years, manageable with reintervention if needed. Advantages of CAS include its minimally invasive nature, shorter recovery time, and avoidance of neck dissection, making it appealing for frail or elderly patients. Yet, long-term data reveal challenges, including a slightly elevated risk of late stroke in certain subgroups, such as those over 75, where cerebral microembolization may be less tolerated [6].

The choice between CEA and CAS hinges on patient-specific factors and long-term goals. CEA remains the preferred option for younger, healthier patients with symptomatic stenosis, given its proven track record and lower early stroke risk. CAS, however, has carved out a niche for high-surgical-risk patients and those with anatomical challenges, such as restenosis after prior CEA. Both procedures benefit from adjunctive medical therapy statins, antihypertensives, and antiplatelets which enhances long-term outcomes by stabilizing plaques and reducing systemic atherosclerosis progression [7]. Advances in technique, such as transcarotid artery revascularization (TCAR), a hybrid approach combining stenting with flow reversal for embolic protection, promise to further refine outcomes, with early studies suggesting lower stroke rates than traditional CAS. Regardless of method, long-term success depends on meticulous patient selection, operator expertise, and sustained risk factor management, as untreated hypertension or smoking can undermine surgical benefits over time [8].

Conclusion

Surgical interventions for carotid stenosis carotid endarterectomy and carotid artery stenting represent cornerstone therapies in the prevention of stroke, each offering distinct advantages and challenges that shape their long-term outcomes. CEA’s established efficacy and durability make it a benchmark for severe symptomatic stenosis, delivering sustained stroke reduction with acceptable risks when performed skillfully. CAS, while initially riskier, provides a viable alternative for patients unfit for open surgery, matching CEA’s long-term efficacy in diverse populations. Both approaches underscore the importance of tailoring treatment to individual profiles, balancing immediate procedural hazards against the prolonged threat of cerebrovascular events. The evidence suggests that, over decades, these interventions significantly alter the natural history of carotid stenosis, transforming a potentially fatal condition into a manageable one for many patients.

Looking forward, the management of carotid stenosis stands at a crossroads of innovation and refinement. Emerging techniques like TCAR and improvements in imaging and medical therapy promise to enhance outcomes further, potentially narrowing the gap between surgical options. However, the long-term success of any intervention hinges on addressing the underlying atherosclerotic process through lifestyle and pharmacological means, as surgery alone cannot halt systemic disease progression. Clinicians must weigh the robust data from trials like NASCET and CREST against real-world variables age, comorbidities, and patient preference to optimize care. As the global burden of stroke persists, understanding and improving the long-term outcomes of CEA and CAS will remain vital, ensuring that surgical advances translate into meaningful gains in survival and quality of life. Ultimately, these interventions exemplify medicine&rsquos capacity to confront vascular disease head-on, offering patients a chance to rewrite their futures beyond the shadow of carotid stenosis.

Acknowledgement

None

Conflict of Interest

None

References

1. Ross R (1999) N Engl J Med 340: 115-126.

   , ,

2. Ross (1986) N Engl J Med 314: 488-500.

   , ,

3. Newby AC (2000) Toxicol Lett 112: 519-529.

   , ,

4. Hansson GK, Jonasson L (2009) Arterioscler. Thromb Vasc Biol 29: 1714-1717.

   , ,

5. Libby P, Ridker PM, Maseri A (2002) Circulation 105: 1135-1143.

   , ,

6. Gistera A, Hansson GK (2017) Nat Rev Nephrol 13: 368-380.

   , ,

7. Tabas I, Lichtman AH (2021) Immunity 47: 621-634.

   , ,

8. Crea F, Libby P (2017) Circulation 136: 1155-1166.

   , ,